196 related articles for article (PubMed ID: 36121452)
21. A novel and robust pyroptosis-related prognostic signature predicts prognosis and response to immunotherapy in esophageal squamous cell carcinoma.
Zhang D; Zhao F; Li J; Qin X; Li S; Niu R
Aging (Albany NY); 2023 Aug; 15(15):7811-7830. PubMed ID: 37561524
[TBL] [Abstract][Full Text] [Related]
22. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
24. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
[TBL] [Abstract][Full Text] [Related]
26. Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma.
Cheng J; Guo M; Yang Y; Liu Y; Hu W; Shang Q; Li C; Xia L; Wang Y; Wang W; Tian D; Yuan Y; Hu Y; Chen L
Front Immunol; 2022; 13():848881. PubMed ID: 35371089
[TBL] [Abstract][Full Text] [Related]
27. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
[TBL] [Abstract][Full Text] [Related]
28. A more novel and robust gene signature predicts outcome in patients with esophageal squamous cell carcinoma.
Ma C; Luo H
Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102033. PubMed ID: 36265781
[TBL] [Abstract][Full Text] [Related]
29. MXD1 is a Potential Prognostic Biomarker and Correlated With Specific Molecular Change and Tumor Microenvironment Feature in Esophageal Squamous Cell Carcinoma.
Du F; Dong D; Zhang X; Jia J
Technol Cancer Res Treat; 2021; 20():15330338211052142. PubMed ID: 34761715
[No Abstract] [Full Text] [Related]
30. Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.
Nobel TB; Barbetta A; Hsu M; Tan KS; Pinchinat T; Schlottmann F; Bains MS; Ku GY; Wu AJ; Patti MG; Jones DR; Molena D
J Gastrointest Surg; 2019 Jan; 23(1):11-22. PubMed ID: 30215197
[TBL] [Abstract][Full Text] [Related]
31. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
[TBL] [Abstract][Full Text] [Related]
32. SPI1-Mediated Upregulation of the
Luo FF; Wang J; Zhang ZF; Lin ST; Huang TJ; Liu BQ; Fan ML; Peng LX; Zheng ST; Yang CF; Huang BJ
Front Biosci (Landmark Ed); 2023 Sep; 28(9):212. PubMed ID: 37796690
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
[TBL] [Abstract][Full Text] [Related]
34. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma.
Yao Y; Xuan H; Wang J; Gong L; Gao W
Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074
[TBL] [Abstract][Full Text] [Related]
35. Practical value of identifying circulating tumor cells to evaluate esophageal squamous cell carcinoma staging and treatment efficacy.
Chen W; Li Y; Yuan D; Peng Y; Qin J
Thorac Cancer; 2018 Aug; 9(8):956-966. PubMed ID: 29893036
[TBL] [Abstract][Full Text] [Related]
36. Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers.
Ma F; Li Y; Xiang C; Wang B; Lv J; Wei J; Qin Z; Pu Y; Li K; Teng H; Tan S; Feng J; Shang Z; Wang Y; Tian S; Du C; Han Y; Ding C
J Hematol Oncol; 2024 Mar; 17(1):11. PubMed ID: 38491392
[TBL] [Abstract][Full Text] [Related]
37. Applying Untargeted Lipidomics to Evaluate the Efficacy of Combined Neoadjuvant Chemotherapy and Immunotherapy for Esophageal Squamous Carcinoma Treatment.
Lin W; Si X; Zhao Z; Chen F; Xu J; Huang W; Lin J; Chen Z; Huang Z
J Proteome Res; 2024 Feb; 23(2):663-672. PubMed ID: 38175711
[TBL] [Abstract][Full Text] [Related]
38. High expression of RABL6 promotes cell proliferation and predicts poor prognosis in esophageal squamous cell carcinoma.
Feng Y; Yan S; Huang Y; Huang Q; Wang F; Lei Y
BMC Cancer; 2020 Jun; 20(1):602. PubMed ID: 32600359
[TBL] [Abstract][Full Text] [Related]
39. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
40. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
